Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C24H28N2O5 |
| Molecular Weight | 424.4895 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@@H]2CCC3=C(C=CC=C3)N(CC(O)=O)C2=O
InChI
InChIKey=XPCFTKFZXHTYIP-WOJBJXKFSA-N
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m1/s1
| Molecular Formula | C24H28N2O5 |
| Molecular Weight | 424.4895 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.lgcstandards.com/CN/en/Benazepril-Related-Compound-A/p/USP1048620 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdfhttps://www.google.com/patents/WO2006084761A1 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdf | http://usp35.infostar.com.cn/uspnf/pub/data/v35300/usp35nf30s0_m7495.html
Sources: https://www.lgcstandards.com/CN/en/Benazepril-Related-Compound-A/p/USP1048620 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdfhttps://www.google.com/patents/WO2006084761A1 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdf | http://usp35.infostar.com.cn/uspnf/pub/data/v35300/usp35nf30s0_m7495.html
BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and also in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.1 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | BENAZEPRIL HYDROCHLORIDE Approved UseBenazepril hydrochloride tablets are indicated for the treatment of hypertension. They
may be used alone or in combination with thiazide diuretics. Launch Date6.777216E11 |
|||
Sample Use Guides
In Vitro Use Guide
Curator's Comment: In the isolated rabbit aorta the vasocontraction induced by PGF2 alpha was competitively antagonized at 10(-5)-10(-4) mol/l, while vascular responses induced by PGE1, PGE2 or PGI2 was inhibited at 3 x 10(-4) mol/l of benazepril. https://www.ncbi.nlm.nih.gov/pubmed/2080946
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:58:25 UTC 2023
by
admin
on
Sat Dec 16 06:58:25 UTC 2023
|
| Record UNII |
PX47FSF9B3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51698396
Created by
admin on Sat Dec 16 06:58:26 UTC 2023 , Edited by admin on Sat Dec 16 06:58:26 UTC 2023
|
PRIMARY | |||
|
PX47FSF9B3
Created by
admin on Sat Dec 16 06:58:26 UTC 2023 , Edited by admin on Sat Dec 16 06:58:26 UTC 2023
|
PRIMARY | |||
|
98626-50-7
Created by
admin on Sat Dec 16 06:58:26 UTC 2023 , Edited by admin on Sat Dec 16 06:58:26 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
